High-Amplitude and Prolonged Glucose Excursions as a Key Determinant of Discordance Between Glucose Management Indicator and Glycated Hemoglobin in Type 1 Diabetes
- 4 May 2026
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (7) , 1221-1230
Abstract
OBJECTIVE: Discordance between the glucose management indicator (GMI) and hemoglobin A1c (HbA1c) is frequently observed in diabetes, yet its physiological basis remains unclear. This study investigated how specific glucose excursion patterns captured by continuous glucose monitoring (CGM) contribute to this discordance in individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS: Ninety-day CGM traces from 611 adults with type 1 diabetes were paired with HbA1c results obtained within ±15 days. Glucose excursions were quantified using the glucose rate increase detector (GRID) algorithm with varied peak glucose and time-to-peak thresholds. Discordance was defined using GMI-to-HbA1c and updated GMI (uGMI)-to-HbA1c ratios, and associations with GRID-derived excursion metrics were evaluated alongside conventional CGM-derived variability metrics. RESULTS: Excursions with peak glucose ≥250 mg/dL and time to peak ≥90 min were significantly associated with higher uGMI-to-HbA1c ratios after adjustment for age, sex, estimated glomerular filtration rate, and HbA1c group, with consistent findings across CGM devices (sensor type 1: β = 0.174, 95% CI 0.147–0.201; sensor type 2: β = 0.102, 95% CI 0.068–0.136; both P < 0.001) and alternative GMI formulations. In restricted cubic spline analyses, adjustment for GRID-derived excursion metrics differentially reshaped the associations of HbA1c, GMI, and uGMI with albuminuria and elevated triglyceride-glucose index in an outcome- and context-dependent manner, preferentially enhancing the informativeness of GMI and uGMI but not HbA1c. CONCLUSIONS: Frequent high and prolonged glucose excursions were consistently associated with GMI-HbA1c discordance across devices, HbA1c strata, and analytic conditions. GRID-derived excursion metrics modify the relationship between GMI/uGMI and glycemia-associated risk.Keywords
All Related Versions
Funding Information
- National Research Foundation of Korea (No. RS-2023-00262002)
This publication has 26 references indexed in Scilit:
- Association of HbA1c and an updated glucose management indicator (uGMI) with incident diabetic retinopathy in adults with type 1 diabetes: a longitudinal studyDiabetologia, 2025
- Identification of clinically meaningful automatically detected postprandial glucose excursions in individuals with type 1 diabetes using personal continuous glucose monitoringDiabetes Research and Clinical Practice, 2025
- Continuous Glucose Monitoring Metrics and Hemoglobin A1c Relationship in Patients with Type 2 Diabetes Treated by HemodialysisDiabetes Technology & Therapeutics, 2024
- The related factors affecting the relationship between HbA1c and glucose management indicator in adult T2D patients with good glycemic controlEndocrine, 2024
- Continuous glucose monitoring with structured education in adults with type 2 diabetes managed by multiple daily insulin injections: a multicentre randomised controlled trialDiabetologia, 2024
- Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trialDiabetologia, 2024
- HbA1c and Glucose Management Indicator Discordance: A Real-World AnalysisDiabetes Technology & Therapeutics, 2021
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987